Effective Management of 177Lu-DOTA0-Tyr3-Octreotate Extravasation - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Clinical Nuclear Medicine Year : 2021

Effective Management of 177Lu-DOTA0-Tyr3-Octreotate Extravasation

Bruno Maucherat
  • Function : Author
CRLCC René Gauducheau
Nicolas Varmenot
  • Function : Author
Nuclear Oncology
CRLCC René Gauducheau
Vincent Fleury
  • Function : Author
  • PersonId : 1037034
  • IdRef : 317200647
CRLCC René Gauducheau
Helene Senellart
  • Function : Author
CRLCC René Gauducheau
Caroline Rousseau
Nuclear Oncology
CRLCC René Gauducheau

Abstract

Radiopharmaceutical extravasation is a known nuclear medicine adverse effect, mostly with no complication in case of diagnostic radiopharmaceutical. However, a therapeutic radiopharmaceutical extravasation may have clinical consequences and must be treated quickly and effectively. We report here a case of 177Lu-DOTA0-Tyr3-octreotate extravasation.

Domains

Cancer

Elizabeth Bernardo  : Connect in order to contact the contributor

https://www.hal.inserm.fr/inserm-03540776

Submitted on : Monday, January 24, 2022-11:19:11 AM

Last modification on : Thursday, May 11, 2023-5:55:01 PM

Not file

Dates and versions

inserm-03540776 , version 1 (24-01-2022)

Identifiers

Cite

Bruno Maucherat, Nicolas Varmenot, Vincent Fleury, Helene Senellart, Caroline Rousseau. Effective Management of 177Lu-DOTA0-Tyr3-Octreotate Extravasation. Clinical Nuclear Medicine, 2021, 46 (2), pp.144-145. ⟨10.1097/RLU.0000000000003452⟩. ⟨inserm-03540776⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

INSERM UNIV-NANTES CNRS UNIV-ANGERS FNCLCC ICO GAUDUCHEAU CRCINA NANTES-UNIVERSITE
11 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More